Live Quote · NASDAQNXTCHealthcare· Biotechnology

NextCure, Inc.

$1.88 3.59%($-0.07)
TickerSpark Score
58/100
Mixed
100
Valuation
20
Profitability
55
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXTC research report →

52-Week Range2% of range
Low
$1.55
Current
$1.88
High
$15.74
Company Overviewwww.nextcure.com

About the company

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function.

CEO
Michael S. Richman
IPO
2019
Employees
43
HQ
Beltsville, MD, US

Price Chart

-63.42% · this period
$14.27$7.93$1.60Jul 02Dec 31Jul 02
Valuation
Market Cap
$5.04M
P/E
-0.10
P/S
0.00
P/B
0.37
EV/EBITDA
0.10
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-186.96%
ROIC
-174.59%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-55,844,000 · -0.34%
EPS
$-19.65 · 17.71%
Op Income
$-57,616,000
FCF YoY
-20.19%
Performance & Tape
52W High
$15.74
52W Low
$1.55
50D MA
$6.06
200D MA
$9.66
Beta
1.30
Avg Volume
99.81K

Get TickerSpark's AI analysis on NXTC

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 18, 26Feigal Ellenother2,340
Jun 18, 26Jones Elaine Vother2,340
Jun 18, 26Borgman Anne Elizabethother2,340
Jun 18, 26Webster Stephen Wother2,340
Jun 18, 26KABAKOFF DAVID Sother3,510
Jun 18, 26Houston John Gother2,340
Jan 30, 26Shaw Kevin G.other8,270
Jan 30, 26Guha Udayanother14,670
Jan 30, 26Kundu Souravother8,270
Jan 30, 26Mayer Timothyother14,670
Coverage · NXTC

Our NXTC coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on NXTC yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate NXTC report →
Internal Compare

Similar companies

Peers in the same neighborhood.